Repligen Corporation (RGEN) Stock Analysis
Falling Knife setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $104.83, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Expensive valuation.
Repligen develops and commercializes bioprocessing products across four franchises—Filtration, Chromatography, Process Analytics, and Proteins—serving global biopharmaceutical manufacturers and CDMOs. Revenue is driven by consumable/single-use product sales with ~2,000 employees... Read more
Hold if already holding. Not a fresh buy at $104.83, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Expensive valuation. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.4/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Repligen Corporation
Latest news
- Is Repligen Corp (RGEN) a Bargain After 3.7% Drop? GF Value Says Undervalued - GuruFocus — GuruFocus positive
- Repligen Corp (RGEN) Stock Up 4.2% and Still Undervalued -- GF S - GuruFocus — GuruFocus positive
- Repligen Corp (RGEN) Stock Down 5.8% -- Now Undervalued? GF Scor - GuruFocus — GuruFocus negative
- Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - StockStory — StockStory negative
- Repligen (RGEN) to Release Earnings on Tuesday - MarketBeat — MarketBeat neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $104.83, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Expensive valuation. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $160.86 (+53.4%), stop $97.96 (−7.0%), A.R:R 4.6:1. Score 5.4/10, moderate confidence.
Take-profit target: $160.86 (+54.4% upside). Target $160.86 (+53.4%), stop $97.96 (−7.0%), A.R:R 4.6:1. Stop-loss: $97.96.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Expensive valuation; Negative momentum.
Repligen Corporation trades at a P/E of 114.5 (forward 40.8). TrendMatrix value score: 3.9/10. Verdict: Hold.
29 analysts cover RGEN with a consensus score of 4.1/5. Average price target: $179.
What does Repligen Corporation do?Repligen develops and commercializes bioprocessing products across four franchises—Filtration, Chromatography, Process...
Repligen develops and commercializes bioprocessing products across four franchises—Filtration, Chromatography, Process Analytics, and Proteins—serving global biopharmaceutical manufacturers and CDMOs. Revenue is driven by consumable/single-use product sales with ~2,000 employees and manufacturing across the U.S., Europe, and Asia.